Phorbol as a possible systemic promoting agent for skin carcinogenesis.
In a repetition of a previous experiment, using this time a 20-fold higher dose of phorbol, administered i.p. as potential (systemic) promotor for skin carcinogenesis, 6/22 (27%) of the treated mice (after a single skin application of DMBA as initiator) developed papillomas, as compared to 1/20 (5%) in the DMBA control group. Though the difference is statistically no more than of borderline significance (P less than 0.05), it does raise the possibility that unesterified phorbol is, after all, a weak promotor for skin carcinogenesis.


BACKGROUND
DMBA equals 7,12-dimethylbenz(a)anthracene. TPA equals 12-0-tetradecanoyl-phorbol-13-acetate.
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000494:pharmacology; D000818:Animals; D004357:Drug Synergism; D005260:Female; D007274:Injections, Intraperitoneal; D051379:Mice; D008813:Mice, Inbred ICR; D009374:Neoplasms, Experimental / Q000139:chemically induced; D010212:Papilloma / Q000139:chemically induced; D010704:Phorbols / Q000494:pharmacology*; D012878:Skin Neoplasms / Q000139:chemically induced*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*
D010704:Phorbols; D015127:9,10-Dimethyl-1,2-benzanthracene; D013755:Tetradecanoylphorbol Acetate